- Conditions
- Diabetic Retinopathy
- Interventions
- Finerenone (BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Heart Failure
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 6,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
- Conditions
- Diabetic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
- Conditions
- Non-diabetic Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 57
- States / cities
- Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
- Conditions
- Kidney Transplant; Complications
- Interventions
- Finerenone Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 13
- States / cities
- Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more